Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22652888 | 0.94 | LIPG (0.62) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL15301292 | 0.94 | LIPG (0.62) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL15496904 | 0.94 | LIPG (0.62) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL15803116 | 0.90 | LPL (0.46) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL5801922 | 0.90 | CA1 (0.49) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL20639944 | 0.86 | KDM4E (0.51) | LPLLIPGESR2 | |
| SCHEMBL23635769 | 0.84 | LIPG (0.55) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL23624415 | 0.84 | LIPG (0.55) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL25897184 | 0.83 | LIPG (0.57) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL20699261 | 0.83 | LIPG (0.58) | LPLLIPGESR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | claimed |
| CN-116356352-A | Method for preparing arylate diamine compound electrochemically | 贵州民族大学 | 2023-06-30 | — | — | CN | claimed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| CN-114342141-A | Elimination of voltage delay and stabilization of impedance by electrolyte additives in alkali metal electrochemical cells | 利特罗尼克电池技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112533915-A | Aggregation-induced blue light material, preparation method thereof and display device | 深圳市柔宇科技股份有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-108178737-B | 4 '- (4-bromonaphthalene-1-yl) [1, 1' -biphenyl ] -4-nitrile and synthesis method thereof | 河南省科学院化学研究所有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-111253285-A | High fluorescence quantum efficiency material based on terphenyl derivative and preparation method thereof | 南京邮电大学 | 2020-06-09 | — | — | CN | claimed |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-6818649-B2 | 5-(8-ALKOXY)-2,2-SUBSTITUTED-2H-CHROMEN-6-YLMETHYL)-PYRIMIDINE-2,4 -DIAMINE DERIVATIVES USEFUL FOR TREATING INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-11-16 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | BASILEA PHARMACEUTICA AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| EP-1278742-A1 | CHROMENYLMETHYLPYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | Basilea Pharmaceutica AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083476-A1 | CHROMENYLMETHYL PYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | TK1, TPMT, CTSL | LPL 2626/4885LIPG 4694/4885ESR2 3771/4885 |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | KCNN1, HCN4, KCNN2 | LPL 4624/4885LIPG 4122/4885ESR2 2348/4885 |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | PC, CS, IDH2 | LPL 496/4885LIPG 180/4885ESR2 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.